Jun 25 |
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
|
Jun 17 |
Keros Therapeutics appoints Jasbir S. Seehra as Chair of board
|
Jun 17 |
Keros Therapeutics Announces Leadership Updates
|
Jun 17 |
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
|
Jun 10 |
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
|
Jun 4 |
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
|
Jun 3 |
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
May 28 |
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
|
May 10 |
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
|
May 8 |
Keros Therapeutics GAAP EPS of -$1.21 beats by $0.12
|